Novartis drops pursuit of Gen-Probe - WSJ

CHICAGO, July 19 Tue Jul 19, 2011 3:20pm EDT

CHICAGO, July 19 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) is no longer actively pursuing a purchase of diagnostic test maker Gen-Probe Inc GPRO.O, the Wall Street Journal said, citing people familiar with the matter.

Shares of Gen-Probe, a maker of tests for infectious diseases, fell $2.51, or 3.92 percent, to $61.48 after the report.

Novartis was thought to be the sole remaining suitor for Gen-Probe after other potential buyers including Life Technologies CorpLIFE.O and Thermo Fisher Scientific Inc (TMO.N) ended their pursuit last month, the sources told the Journal in a story on its website.

Another bidder could still emerge because the sale process is ongoing, other people familiar with the matter told the Journal.

A Novartis spokeswoman declined to comment on the report.

A spokesman for San Diego-based Gen-Probe, a maker of tests for infectious diseases, also declined to comment.

(Reporting by Susan Kelly, editing by Bernard Orr)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.